- A meta-analysis shows efficacy of cytokine-induced killer cell/dendritic cell combined with cytokine-induced killer cell immunotherapy (CIK/DC-CIK) in the treatment of advanced gastrointestinal (GI) cancer.
Why this matters
- This form of immunotherapy has been tested in multiple clinical trials, with mixed results.
- Meta-analysis of 9 studies (n=1113).
- Funding: None.
- Chemotherapy plus immunotherapy was associated with longer PFS than chemotherapy alone (risk ratios, 95% CIs) at:
- 1 year: 1.34 (1.13-1.59);
- 3 years: 1.39 (1.20-1.62); and
- 5 years: 1.99 (1.52-2.60).
- Groups did not differ significantly in rates of complete response, partial response, or overall response rate.
- Immunotherapy plus chemotherapy was associated with better QoL than was chemotherapy alone (weighted mean difference, 16.09; 95% CI, 1.66-30.52).
- Groups did not differ significantly with respect to rates of thrombocytopenia, nausea, vomiting, abnormal liver function, neutropenia, or myelosuppression.
- Various subgroup analyses returned similar results to the overall analysis.
- Multiple factors affect CIK/DC-CIK immunotherapy, including injection mode, tumor stage, and metastasis cycle, and these differences were not accounted for.
- The analysis included publishing bias and heterogeneity that could not be completely eliminated.